Switching from tirzepatide to retatrutide: what's possible

The short answer: you cannot lawfully switch from tirzepatide to retatrutide through a prescription today. Retatrutide is investigational, and the manufacturer says it is legally available only to participants in its clinical trials. [1] The lawful options are a registered clinical trial or, for a narrow group of patients, a pre-approval expanded access program that a treating physician has to request. [2]

This guide covers what those routes ask of someone already taking tirzepatide, how the two drugs differ, and why products sold online as "research" retatrutide are not a lawful switch. It does not cover dosing, dose conversion, or changing from one drug to the other.

Can you switch from tirzepatide to retatrutide?

Not through a prescriber or pharmacy. Tirzepatide is FDA approved and sold as Zepbound, with a label that sets out its uses, warnings, and limits. [3] Retatrutide has no approval. FDA states that it cannot be used in compounding under federal law, because it is not a component of an FDA-approved drug and has not been found safe and effective for any condition. [4] FDA has also warned telehealth companies for marketing unapproved drugs such as retatrutide to consumers. [4]

That leaves two lawful routes, both outside ordinary prescribing:

• A clinical trial, where the study protocol, not your prescriber, decides who receives retatrutide.
• Expanded access, a pre-approval program for people with severe obesity that has not responded to approved therapy, requested by a treating physician.

The legal record is logged on the retatrutide regulatory tracker, and our guide to how to get retatrutide walks through trial search and expanded access step by step. This post focuses on the part specific to people already on tirzepatide.

Do retatrutide trials accept people already taking tirzepatide?

Usually not at the point of screening. The registered retatrutide obesity trials list recent weight loss medication as an exclusion, and the wording is consistent across the program.

• TRIUMPH-1 (adults with obesity or overweight, now completed) excluded anyone who had taken weight loss drugs, including over-the-counter medications, within 90 days before screening. It also excluded anyone with a self-reported or documented change in body weight of more than 5 kg (11 pounds) within 90 days. [5]
• TRIUMPH-5, the head-to-head trial against tirzepatide, lists the same two exclusions: weight loss drugs within 90 days and a weight change of more than 5 kg within 90 days. [6]
• A recruiting phase 2 trial (NCT07467447) excludes use within the prior 3 months of medications or remedies intended to promote weight loss and names GLP-1 receptor agonists among the examples. It also excludes metformin and other glucose-lowering medications at entry, and anyone who previously received retatrutide (LY3437943) in this or another study. [7]

Read plainly, someone currently taking tirzepatide for weight would not meet these criteria at screening, and someone who has recently lost a lot of weight on it may not either. The study team makes the final eligibility decision, and criteria differ by trial, so read each listing in full.

One caution matters more than the rest. Do not stop a prescribed drug on your own in the hope of qualifying for a trial. In SURMOUNT-4, adults who were switched from tirzepatide to placebo after a 36 week lead-in had a mean weight change of plus 14.0% over the next 52 weeks, versus minus 5.5% for those who continued. [8] Trials also randomize some participants to placebo, so enrolling does not guarantee you will receive retatrutide. Any decision to stop tirzepatide belongs with your prescriber, made with the trial's actual criteria in hand.

Openings are limited. On October 12, 2026, a ClinicalTrials.gov search for retatrutide as the intervention returned 33 records: 21 completed, 9 active but not recruiting, 2 recruiting, and 1 expanded access record marked available. [9]

Is there expanded access for people who have maxed out tirzepatide?

This is the one route written with people already on approved therapy in mind. The manufacturer's pre-approval expanded access program on ClinicalTrials.gov requires all of the following: [2]

• Age 18 or older.
• A BMI of 35 or higher despite adherence to and tolerance of the highest available dose of chronic weight management therapy.
• Two or more serious or life-threatening obesity-related complications currently being treated.
• Inability to join an ongoing retatrutide trial or a comparable investigational trial, because of eligibility criteria or distance.
• All standard options, including bariatric surgery, discussed through shared decision-making.

The treating physician starts the request. This fits FDA's general description of expanded access as a pathway for a patient with a serious or immediately life-threatening condition to receive an investigational product outside a trial when no comparable or satisfactory alternative exists. [10] For most people who are responding to tirzepatide, an approved drug that works is that satisfactory alternative.

How do tirzepatide and retatrutide differ?

Mechanism. Tirzepatide is a GIP receptor and GLP-1 receptor agonist. [3] Retatrutide activates those two receptors plus the glucagon receptor, which makes it a triple agonist. [11] [12] The glucagon arm is the new part.

Trial results. In its phase 2 obesity trial of 338 adults, retatrutide's top dose produced a mean weight change of minus 24.2% at 48 weeks versus minus 2.1% on placebo, and heart rate rose with dose, peaking at 24 weeks before declining. [11] In SURMOUNT-1, tirzepatide's top dose produced minus 20.9% at 72 weeks versus minus 3.1% on placebo. [13] These are different trials with different populations and durations, so the numbers cannot be compared directly.

Head-to-head data. A direct comparison is under way but has not reported. TRIUMPH-5 is a phase 3, randomized, double-blind trial of retatrutide against tirzepatide in adults with obesity, with an estimated 800 participants and percent change in body weight as the primary outcome. It is listed as active and not recruiting, with no results posted as of October 12, 2026. [6] Until it reports, our tirzepatide vs retatrutide comparison lines up the separate trials and says where they cannot be compared.

Regulatory maturity. Tirzepatide has an approved label with defined warnings, and that label states that taking it together with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended. [3] Retatrutide's safety is known only from trials, and FDA has not reviewed the full data. For the trial safety findings, see retatrutide side effects, and for the state of the phase 3 program, see where the phase 3 program stands.

Why is research-use retatrutide not a lawful switch?

Products sold online as retatrutide are not a gray area. FDA has warned companies that illegally sold unapproved drugs containing retatrutide that were falsely labeled "for research purposes" or "not for human consumption," and sold directly to consumers for human use with dosing instructions. [4] In an August 2026 warning letter, FDA found an online seller offering retatrutide as "GLP-3 Reta" and called it an unapproved new drug despite its research-use-only labels. [14]

The risk is not only legal. A 2026 case report described a man with type 1 diabetes hospitalized with high ketones and acute kidney injury after injecting an online product sold as retatrutide; a gut infection was also present, and the authors pointed to uncertain composition and dosing as part of the risk. [15]

What should you do instead?

If you are on tirzepatide and wondering whether retatrutide would do more, these steps stay within lawful, supervised care:

1. Talk to your prescriber first. Say why you are asking: weight loss has stalled, side effects are hard to tolerate, or cost is a problem. Each has options within approved therapy that your prescriber can review against the label.
2. Stay on approved therapy unless your prescriber advises otherwise. The SURMOUNT-4 data show what stopping can mean. [8]
3. Search for a trial, and bring it to your prescriber. Use ClinicalTrials.gov, filter for recruiting studies, and read the exclusion criteria on prior weight loss drugs before you change anything. Ask the study team how the protocol handles current medications. [9]
4. Ask about expanded access only if you meet its criteria. It is for severe, treatment-resistant obesity, and the request comes from your physician. [2]
5. Follow the approval record. If retatrutide is approved, it will have a label, and switching becomes a prescribing question with real guidance. The retatrutide regulatory tracker logs each filing and decision as it happens.